AcelRx jumps on deal to commercialize opioid-based pain treatment in Europe

Talphera

14/07/2021 15:41

** Shares of drugmaker AcelRx Pharmaceuticals Inc  ACRX.O 
jump ~18% to $1.44, set for their biggest daily pct gain in
nearly 6 months
    ** ACRX announces deal with Aguettant to commercialize its
opioid pain management drug in Europe
    ** Dsuvia, known as Dzuveo in Europe, is used to relieve
severe pain in medically supervised settings
    ** AcelRx will receive up to ~$55 mln in a combination of
up-front and sales-based milestone payments along with revenue
share payments ranging from 35%-45% of net sales  urn:newsml:reuters.com:*:nPn5h1kX5a
    ** Under a separate licensing agreement, AcelRx to
commercialize two of Aguettant's EU-approved, pre-filled syringe
products in the U.S. after approval from FDA
    ** YTD, stock up 16%

 (Reporting by Shreyasee Raj in Bengaluru)
 ((Shreyasee.Raj@thomsonreuters.com;))